Af­ter culling work­force, mi­graine biotech Zosano drops lead — and sole — pro­gram

It ap­pears Zosano may not have much left in the tank.

In April, the mi­graine-fo­cused biotech an­nounced that it would cull about a third of its work­force — less than a month af­ter the FDA re­fused to re­view the com­pa­ny’s re­sub­mis­sion for its mi­graine treat­ment patch known as M207. The agency said that the com­pa­ny didn’t ad­e­quate­ly re­spond to the de­fi­cien­cies iden­ti­fied in the FDA’s ini­tial, 2020 CRL.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER